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Human Papillomavirus E7 Induces Rereplication in Response to DNA
Damage
Xueli Fan, Yingwang Liu,* Susan A. Heilman, Jason J. Chen
Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
Human papillomavirus (HPV) infection is necessary but not sufficient for cervical carcinogenesis. Genomic instability caused by
HPV allows cells to acquire additional mutations required for malignant transformation. Genomic instability in the form of
polyploidy has been demonstrated to play an important role in cervical carcinogenesis. We have recently found that HPV-16 E7
oncogene induces polyploidy in response to DNA damage; however, the mechanism is not known. Here we present evidence
demonstrating that HPV-16 E7-expressing cells have an intact G2 checkpoint. Upon DNA damage, HPV-16 E7-expressing cells
arrest at the G2 checkpoint and then undergo rereplication, a process of successive rounds of host DNA replication without en-
tering mitosis. Interestingly, the DNA replication initiation factor Cdt1, whose uncontrolled expression induces rereplication in
human cancer cells, is upregulated in E7-expressing cells. Moreover, downregulation of Cdt1 impairs the ability of E7 to induce
rereplication. These results demonstrate an important role for Cdt1 in HPV E7-induced rereplication and shed light onmecha-
nisms by which HPV induces genomic instability.
Genomic instability is a hallmark of cancer progression (1).Genomic instability in the form of polyploidy, wherein cells
have more than two sets of chromosomes, has been implicated as
a causal factor in tumorigenesis (2, 3). Tetraploidy in basal kera-
tinocytes has been found in low-grade squamous intraepithelial
lesions of the cervix infected with high-risk but not low-risk hu-
man papillomavirus (HPV) types (4). Significantly, it was demon-
strated that tetraploidy occurred as an early event during cervical
carcinogenesis and predisposed cells to aneuploidy that is consis-
tently observed in all cancers (5). Polyploidy can be formed via
rereplication, a process in which origins fire more than once
within a single S phase, or endoreduplication, in which multiple S
phases occur without an intervening mitosis (6). Endoreduplica-
tion can occur in G2, earlymitosis, or S phase. In the literature, the
term rereplication has often been used for both rereplication and
endoreduplication (6). To reduce confusion, we will use the term
rereplication for DNA rereplication that occurs within the same
interphase and endoreduplication for DNA rereplication that oc-
curs after cells enter into mitosis. Rereplication can lead not only
to polyploidy but also to gene amplification (7), DNA fragmenta-
tion (8), DNA breaks (9), and cellular DNA damage response
(reference 10 and references therein).
Papillomaviruses are small DNA viruses that replicate in the
stratified layers of skin and mucosa. Human papillomaviruses
(HPVs) can be classified as either high or low risk depending on
their clinical associations. The high-risk HPV types, such as
HPV-16 and HPV-18, are commonly associated with lesions that
can progress to high-grade cervical intraepithelial neoplasia and
cervical carcinoma (for a review, see reference 11). The transform-
ing properties of high-risk HPVs reside primarily in the E6 and E7
oncogenes, and the sustained expression of these genes appears to
be essential for the maintenance of the transformed state of HPV-
positive cells (reference 12 and references therein). E6 and E7
from high-risk HPV types induce genomic instability that occurs
early in preneoplastic lesions, when the viral genome still persists
in an episomal state (13, 14). The ability of the high-risk HPV E7
protein to bind and promote the degradation of pRb has been
suggested as a mechanism by which HPV oncogenes promote tu-
mor formation, although E7 also has functions independent of
inactivating pRb (reviewed in reference 13).
Cell cycle progression is regulated at several checkpoints whose
defects contribute to genomic instability (15). The checkpoints in
eukaryotic cells include the G1 checkpoint, the G2 checkpoint, the
spindle assembly checkpoint, and the postmitotic checkpoint
(16). The cell cycle is driven mainly by cyclins and cyclin-depen-
dent kinases (Cdks) (17) and is partly controlled by p53 and pRb
(17, 18). Although it is well documented that HPV E7 abrogates
the G1 checkpoint (13), its effect on the G2 checkpoint is not as
clear. In primary human keratinocytes (PHKs) expressing
HPV-16 E7, an intact G2 checkpoint was implicated after treat-
ment with doxorubicin (Adriamycin) (19). However, interpreta-
tion of this observation is complicated by the fact that doxorubicin
inhibits topoisomerase II that triggers a decatenation checkpoint
(20) in addition to inducing DNA breaks (21). In contrast, mouse
NIH 3T3 cells expressing HPV E7 were thought to be unable to
maintain aG2 arrest after doxorubicin treatment (22). In response
to 60Co, the G2 checkpoint is maintained in human fibroblasts
expressing HPV-16 E7 (23). On the other hand, following hy-
droxyurea treatment, more HPV-16 E7-expressing PHKs than
control cells were found in mitosis (24).
We have recently demonstrated that in response to microtu-
bule disruption, E6 and E7 induced polyploidy through en-
doreduplication, a process including cell arrest at the spindle
checkpoint, mitotic slippage, and abrogation of the postmitotic
checkpoint (25, 26). Induction of polyploidy byHPVE7 inmouse
NIH 3T3 cells treated with doxorubicin was proposed by Polager
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andGinsberg to be a result of endoreduplication, though evidence
was not provided (22). Themechanism bywhich E6 or E7 induces
polyploidy in response to DNA damage therefore remains un-
known.
In the present study, we examined the effect of HPV-16 E7 on
theG2 checkpoint in PHKs and explored themechanism bywhich
E7 induces polyploidy in response to DNA damage.We show that
HPVE7-expressing cells have an intactG2 checkpoint. In response
to DNA damage, HPV E7 induces rereplication. We also demon-
strate a role for the DNA replication initiation factor Cdt1 in E7-
induced rereplication.
MATERIALS AND METHODS
Cell culture. PHKs and cervical epithelial cells (CEs) were obtained from
theUniversity ofMassachusettsHospital. Cervical epithelial cells contain-
ing the HPV-16 genome (CE-HPV) (27) were provided by Aloysius Klin-
gelhutz, University of Iowa. These cells were cultured on mitomycin C-
treated J2-3T3 feeder cells in E medium composed of three parts
Dulbecco’s modified Eagle medium (DMEM) and one part Ham’s F12
medium plus 5% fetal bovine serum (FBS), with all supplements as pre-
viously described (26). The human telomerase reverse transcriptase-ex-
pressing human retinal pigment epithelium cell line (RPE1) was main-
tained in a 1:1 dilution of DMEM-Ham’s F-12 medium plus 10% FBS.
PHKs andRPE1 cells expressingHPV-16E7were established using the
pBabe retroviral system. Early-passage PHKs (within 3 passages) were
used for infection. Retroviruses encoding HPV-16 E7 or vector were pro-
duced by transfection of PA317 or LinXA packaging cells. After transfec-
tion, retrovirus was collected in E medium or RPE1 medium. The PHKs
or RPE1 cells were infected with retroviruses in 8 g/ml hexadimethrine
bromide (Polybrene) for 6 h. Cells were allowed to recover for 24 h and
then selected with 1.25g/ml puromycin (PHKs) or 12.5g/ml puromy-
cin (RPE1) for 3 to 6 days. Populations of infected cells were pooled and
expanded. To ensure that a high percentage of cells will express E7 or
contain the retroviral vector, PHKs and RPE1-derived cell lines were
maintained in puromycin (0.5 g/ml and 6.5 g/ml, respectively) and
used within 10 passages. Parental PHKs do not proliferate well after long-
term culture with such puromycin concentrations.
For UV treatment, the RPE1-Babe or E7 cells were rinsed twice with
phosphate-buffered saline (PBS) and resuspended in PBS during UV ex-
posures. Dishes were uncovered and exposed to UV irradiation using the
germicidalUV lamp in a tissue culture hood for 1min and then released to
regular medium and incubated for 48 h.
Immunoblotting. Protein extraction was prepared in lysis buffer (10
mMTris [pH 7.4], 1% SDS, 1.0mM sodium orthovanadate). The protein
concentration was measured by the bicinchoninic acid (BCA) protein
assay reagent (Pierce) and confirmed byCoomassie blue staining ofmem-
branes after blotting. Equal amounts of protein from each cell lysate were
separated in an SDS polyacrylamide gel (PAGE) and transferred onto a
polyvinylidene difluoride (PVDF) membrane. Membranes were blotted
with antibodies against Cdt1 (a gift from Anita Dutta, Millipore, number
071383, and Santa Cruz Biotechnology, H-300, sc-28262), Cdc25c (Cell
Signaling; number 4688s), p-Cdc25c (Cell Signaling; number 4901s),
-tubulin (Sigma; T-4026), and -actin (Sigma; A-2066). For E7 detec-
tion, whole-cell extracts (150 g) in ML buffer (300 mM NaCl, 0.5%
Nonidet P-40 [NP-40], 20 mM Tris-HCl [pH 8.0], 1 mM EDTA) were
separated by SDS-PAGE, transferred onto a PVDF membrane, and sub-
sequently probed with a mixture of 8C9 (Zymed/Invitrogen; number 28-
0006, at a 1:150 dilution) and ED17 (Santa Cruz Biotechnology; sc-6981,
at a 1:200 dilution). Horseradish peroxidase (HRP)-conjugated goat anti-
mouse and anti-rabbit were used as secondary antibodies. -actin or
-tubulin was used to indicate the loading amount of total proteins.
ImageJ (NIH) was used to quantify gel images.
Immunofluorescence. For phospho-histone H2AX staining, 1.5 
105 cells were seeded onto a 60-mm dish and grown on coverslips. The
following day, cells were treatedwith bleomycin (5g/ml). During 48 h of
treatment, bleomycin was replenished in 24 h. Cells were fixed with 95%
ethanol/5% acetic acid for 5 min at room temperature and blocked with
3% bovine serum albumin (BSA)/Tris-buffered saline (TBS) buffer for 30
min at room temperature. Cells were then incubated with antibody
against phospho-histone H2AX (Millipore; 05-636) for 1 h at a 1:100
dilution, followed by incubation with a fluorescein isothiocyanate
(FITC)-labeled anti-mouse secondary antibody. Cells were washed in
PBS, counterstainedwith 4,5-diamidino-2-phenylindole dihydrochloride
(DAPI; Vector Laboratories), and analyzed with the Olympus BX51 epi-
fluorescence microscope equipped with a multiband filter set. Two-color
images were overlaid using the Nikon NIS-Elements BR 3.10 imaging
software.
Flow cytometry. For cell cycle and polyploidy analysis, asynchronous
cultures of PHKs and RPE1 cells expressing HPV E7 or vector alone were
treated with PBS or bleomycin (Alexis Biochemicals; 5g/ml in PBS). For
CE-HPV or the control, the cells were treated with 200 ng/ml bleomycin.
For cisplatin treatment, cells were incubated for 6 h with 50 M cisplatin
(Sigma), washed with PBS, and incubated with cisplatin-free medium for
42 h. Forty-eight hours later, after the feeder cells were removed, cells were
collected, fixed in 70% ethanol overnight, resuspended in PBS, stained in
propidium iodide (PI) (50 g/ml in PBS; Sigma) staining solution sup-
plemented with 70 g/ml RNase A (Sigma), and analyzed by flow cytom-
etry. Cell cycle analysis was done using FlowJo software (Tree Star, Inc.,
Ashland, OR). For a nocodazole trapping assay, cells were first treated
with 10g/ml bleomycin for 12 h and then incubated with bleomycin (10
g/ml) plus nocodazole (50 ng/ml) for an additional 24 h. For themitotic
marker phospho-histone H3 (P-HH3) staining, cells were fixed in 70%
ethanol, permeabilized in 0.25% Triton X-100, stained with 0.5 g of the
rat anti-phospho-histone H3 (anti-PHH3) immunoglobulin G 2a
(IgG2a) (Sigma), followed by staining with fluorescein isothiocyanate
(FITC)-conjugated anti-rat IgG2a (BD Biosciences), and counterstained
with PBS-PI-RNase A.
For the bromodeoxyuridine (BrdU) labeling experiment, asynchro-
nous cultures of cells were treated with PBS or bleomycin. BrdU (final, 20
M) was added to the medium 2 h before collection of cells. Cells were
then harvested and fixed in 70% ethanol overnight. The cells were perme-
abilized with 2 NHCl-0.5% Triton X-100, neutralized with 0.1M sodium
tetraborate, stained with monoclonal anti-BrdU (BD Biosciences), fol-
lowed by anti-mouse IgG F(ab)2-FITC (Sigma) staining, and counter-
stained with PBS-PI-RNase A.
RNA interference (RNAi). Small interfering RNA (siRNA) oligonu-
cleotides were purchased from Dharmacon, Inc. The siRNA duplexes
were the nonsilencing control siRNA sense strand (5-UUCUCCGAACG
UGUCACGU-3=), Cdt1-siRNA001 (5=-AACGUGGAUGAAGUACCCG
AC-3=) (sense strand, described in reference 28), and Cdt1-siRNA002
(5=-CCUACGUCAAGCUGGACAA-3=) (sense strand, described in refer-
ence 29). For polyploidy analysis, 1.2  105 cells were seeded onto a
60-mmdish the day before transfection. Cells were transfectedwith a final
concentration of 20 nM siRNA per target gene using Lipofectamine 2000
transfection reagent according to the manufacturer’s instructions (Invit-
rogen). The next day after transfection, cells were treated with 4 g/ml
bleomycin, incubated for an additional 36 to 48 h, and then harvested 72
h posttransfection. For protein knockdown analysis, cells were seeded
onto a 60-mmdish the day before siRNA transfection. Seventy-two hours
after transfection, cells were harvested and specific protein levels were
analyzed by immunoblot. For the BrdU labeling experiment, RPE1-E7
cells were transfected with 20 nM siRNA. Thirty-six hours later, the cells
were treatedwith bleomycin (4g/ml) for an additional 36 h. BrdU (final,
20 M) was added to the medium at 2 h before collection of cells. Cells
were then stained and analyzed as described above.
Statistical analysis. All data are shown as means and standard devia-
tions (SDs). The Student t test was used to compare the differences be-
tween means. Significance was set at a P value of0.05.
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RESULTS
PHKs expressing HPV-16 E7 have an intact G2 checkpoint in
response to DNA damage.We have shown previously that upon
DNA damage, PHKs expressing HPV-16 E7 or both E6 and E7
bypassed the G1 checkpoint and accumulated at the G2/M phase
with an increase in cells with more than 4C DNA content (26).
Upon treatment with bleomycin, a radiomimetic (30), newly pre-
pared PHKs from a different individual reproducibly demon-
strated E7-induced polyploidy (Fig. 1A). Similar results were ob-
tained in RPE1 cells expressing HPV-16 E7 (Fig. 1B). Expression
of E7 in both cell types was demonstrated by aWestern blot (data
not shown). Significantly, cervical epithelial cells containing the
HPV-16 genome also became polyploid after bleomycin treat-
ment (Fig. 1C). Cisplatin, another DNA damage agent that has
been widely used to treat cervical cancer, also induced polyploidy
of HPV E7-expressing RPE1 cells (Fig. 1D). The treatment with
the DNA damage agent is biologically relevant, as both E6 and E7
oncogenes from high-risk HPV types induce DNA damage and
genomic instability (31–33). DNA damage may also result from
spontaneous decay, replication errors, and cellular metabolism
(34). Consistent with this notion, spontaneous polyploidization
in PHKs expressing E7 was observed (Fig. 1A). Although no sig-
nificant spontaneous polyploidy was seen in early-passage RPE1
cells expressing E7 (Fig. 1B), over an extended period of culture, a
small but statistically significant increase in the percentage of
polyploidy in these cells has been found (25). Bleomycin treat-
ment enhanced the extent of DNA damage (Fig. 1E).
Next, we extended our studies to determine the integrity of the
G2 checkpoint in early-passage cells expressing E7. Cells in the G2
phase and in mitosis normally have similar DNA contents of 4C.
To distinguish between these two cell populations, we used the
mitotic specificmarker P-HH3 (35) to determine which cells were
inmitosis. Using P-HH3 as amarkermay underestimate the num-
ber of mitotic cells due to sensitivity and tendency of mitotic cells
to detach from the culture dish. The trypsinization and removal
steps for feeder cells before collection of PHKs would further re-
duce the number of mitotic cells. For this concern, we emphasize
the relative numbers of mitotic cells with and without DNA dam-
age. After bleomycin treatment, PHKs expressing E7, like vector
control cells, showed a reduced number of cells expressing
P-HH3, demonstrating that these cells with 4C DNA content are
mainly at G2 and not in mitosis (Fig. 2A). This indicates that the
G2 checkpoint in these cells is intact. Similar results were obtained
in E7-expressing RPE1 cells (Fig. 2B), cervical epithelial cells con-
taining the HPV-16 genome (Fig. 2C), and RPE1-E7 cells treated
with cisplatin (Fig. 2D). We also used DAPI to stain cells in mito-
sis. We counted a total of approximately two thousand regularly
cultured RPE1 cells and identified 1.7% and 1.9%mitotic cells (as
indicated by cells with condensed chromosomes and a lack of a
nuclear membrane) in vector- and E7-expressing cells, respec-
tively. Upon bleomycin treatment, however, no apparent DAPI-
positive cells can be identified frommore than one thousand vec-
tor- or E7-expressing RPE1 cells (data not shown). These results
are consistent with what was observed when P-HH3 was used as
the mitotic marker.
To provide more evidence that the bleomycin-treated cells are
in G2 instead of mitosis, we examined the protein phosphatase
Cdc25c, a protein responsible for dephosphorylation and activa-
tion of Cdk1 (36–38). During interphase, Cdc25C is phosphory-
lated on Ser216 [phospho-Cdc25c (Ser216)] (39). During the
transition from interphase to mitosis, Cdc25c becomes hyper-
phosphorylated (40). As shown in Fig. 2E, upon bleomycin treat-
ment, while undetectable in the vector control cells, Cdc25c in
E7-expressing RPE1 cells is phosphorylated on Ser216 in a form
similar to those in asynchronous cells but different from those in
mitosis (hyperphosphorylated, as demonstrated by the appear-
ance of an upper band in nocodazole-treated cells using antibody
against total Cdc25c). The weak band detected by the antibody
specific to phospho-Cdc25c (Ser216) after nocodazole treatment
suggests that a small percentage of cells are still in interphase,
while the hyperphosphorylated band suggests that somephospho-
Cdc25c (Ser216) may persist during mitosis and can be further
phosphorylated at additional amino acids. These results indicate
that RPE1-E7 cells remain largely in interphase instead of mitosis
after bleomycin treatment. In conjunction with results from flow
cytometry analysis (Fig. 1B) that indicate that the majority of
RPE1-E7 cells contains 4C DNA content, the evidence suggests
that these cells are in the G2 stage of the cell cycle. Based on these
results, we conclude that in HPV E7-expressing cells, while the G1
checkpoint is defective, the G2 checkpoint is largely intact in re-
sponse to DNA damage.
HPV E7-expressing cells undergo rereplication upon DNA
damage. Since E7-expressing cells have an intact G2 checkpoint
and polyploidy occurred without the cells entering mitosis, we
conclude that endoreduplication is not the major mechanism for
E7-expressing cells to become polyploid. However, it remains
possible that a small percentage of cells expressing E7 can enter
intomitosis after DNA damage and lead to endoreduplication. To
test this possibility, we added nocodazole to trap cells that may
have bypassed the G2 checkpoint in mitosis. Our previous studies
have demonstrated that HPV E6 and E7 do not have much effect
on the spindle checkpoint and that cells expressing E7 arrest in
mitosis for an extended period of time (25). As shown in Fig. 3A,
after addition of nocodazole following DNA damage, the percent-
age of P-HH3-positive cells is still very small (0.11%), indicating
that few cells entered mitosis after bleomycin treatment. Further-
more, the percentage of polyploidy formed in PHKs expressing E7
after bleomycin treatment in the presence of nocodazole did not
FIG 1 HPV-16 E7 induces polyploidy uponDNAdamage. Asynchronous cultures of cells were treatedwith PBS, bleomycin, or cisplatin. Forty-eight hours later,
cells were collected, fixed, stained with PI, and analyzed by flow cytometry. (A) PHKs expressing HPV-16 E7 (PHK-E7) or containing the vector (PHK-Babe).
Cells were treated with 5 g/ml bleomycin for 48 h. Data from a representative experiment of 2 individual experiments are shown. (B) RPE1 cells expressing
HPV-16 E7 (RPE1-E7) or containing the vector (RPE1-Babe)were treated as described above. Data from a representative experiment of 5 individual experiments
are shown. (C) Cervical epithelial cells containing the HPV-16 genome (CE-HPV) or control cells (CE) were treated with 200 ng/ml bleomycin for 48 h. Data
from a representative experiment of 4 individual experiments are shown. (D) RPE1-E7 and RPE1-Babe cells were treated with PBS or cisplatin (50 M) for 6 h,
followed by incubation with regular medium for an additional 42 h. Data from a representative experiment of 4 individual experiments are shown. The
percentages of cells with 2C, 4C, andmore than 4CDNA content are indicated. (E) RPE1-E7 and RPE1-Babe cells were treated with PBS or bleomycin (5g/ml)
for 48 h. Indirect immunofluorescence microscopy was performed to detect phospho-histone H2AX (green). DAPI (blue) was used to counterstain the nucleus.
Images were captured at40 magnification.
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FIG 2 HPV-16 E7-expressing cells have an intact G2 checkpoint upon DNA damage. Asynchronous cultures of cells were treated with bleomycin, cisplatin, or
PBS. Cells were collected, fixed, stainedwith rat anti-PHH3 IgG2a and FITC-conjugated anti-Rat IgG2a, counterstainedwith PI, and analyzed by flow cytometry.
(A) PHKs expressing E7 or vector control treated with bleomycin (5g/ml) for 48 h. (B) RPE1-E7 and RPE1-Babe cells treated with bleomycin (5g/ml) for 48
h. (C) Cervical epithelial cells containing the HPV-16 genome or control (PHK) cells treated with bleomycin (200 ng/ml) for 48 h. (D) RPE1-E7 and RPE1-Babe
cells treated with cisplatin (50 M) for 6 h and incubated in regular medium for an additional 42 h. Data from a representative of at least two independent
experiments are shown. The percentages of mitotic cells with 4C DNA content are indicated. (E) p-CDC25c and Cdc25c levels in RPE1 cells expressing E7 or
vector were examined by Western blotting. Asynchronous RPE1 cells expressing E7 or vector were treated with bleomycin (5 g/ml) for 48 h and harvested for
Western blotting or treated with nocodazole (50 ng/ml) for 20 h. Mitotic cells were shaken off the dish and used for a Western blot analysis.
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change significantly compared with that in PHKs treated with
bleomycin alone, suggesting that endoreduplication does not con-
tribute much to polyploidy formation under this experimental
condition. These results suggest that rereplication is the major
mechanism by which E7 induces polyploidy formation in re-
sponse to DNA damage.
To confirm that polyploidy formation in E7-expressing cells is
a result of DNA replication, we measured BrdU incorporation in
E7-expressing cells. As shown in Fig. 3B, after 16 h of bleomycin
treatment, increasing numbers of E7-expressing PHKs with4C
DNAcontent stainedwithBrdUandbecamepolyploid, indicating
that rereplication had occurred. Notably, a significant number
(5%) of E7-expressing PHKs underwent rereplication without
bleomycin treatment, a finding which may be a result of DNA
damage induced by E7. The number of cells with4C DNA con-
tent continued to increase up to 48 h after DNA damage while the
number of P-HH3-positive cells did not change significantly (data
not shown). Similar results were observed inRPE1 cells expressing
FIG 3 HPV-16 E7 induces DNA rereplication upon DNA damage. (A) Asynchronous cultures of PHK-E7 cells were treated with bleomycin (10 g/ml) for 12
h.Nocodazole (50 ng/ml)was added, and cells were cultured for an additional 24 h. Cells were collected, fixed, stainedwith anti-P-HH3 antibody, counterstained
with PI, and analyzed by flow cytometry. Percentages ofmitotic cells with 4C (G2/M)DNA content are indicated. (B) Asynchronous cultures of PHKs, RPE1 cells
expressing E7, and cervical epithelial cells containing the HPV-16 genome were treated with bleomycin (10g/ml, 5g/ml, and 200 ng/ml, respectively) or PBS
for 16 (PHKs) or 48 (other cells) h. Cells were labeled with BrdU for 2 h before collection. Then the cells were stained with anti-BrdU antibody, counterstained
with PI, and analyzed by flow cytometry. The percentages of BrdU-positive cells with DNA content4C are indicated. Data from a representative of at least 2
experiments are shown.
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HPV-16 E7 and cervical epithelial cells containing the HPV-16
genome (Fig. 3B). Together with results shown in Fig. 3A, our
results demonstrate that rereplication is the major mechanism by
which E7 induces polyploidy formation in response to DNA
damage.
TheDNA replication initiating factor Cdt1 is upregulated in
E7-expressing cells. As an initial step toward understanding the
mechanism by which E7 induces rereplication, we examined the
expression of Cdt1, which is the only known mammalian gene
that efficiently triggers rereplicationwhenoverexpressed in cancer
cells (9, 41, 42). As shown in Fig. 4A, the steady-state level of Cdt1
was significantly increased (bymore than 4-fold) in E7-expressing
PHKs compared to that in the vector control PHKs. Notably, an
extra band that is more evident in PHK-E7 cells was observed by
using the antibody (Ab) from Santa Cruz (sc-28262, H-300) (Fig.
4A, upper panel). However, this band is absent in cervical epithe-
lial cells containing the HPV-16 genome and RPE1 cells (Fig. 4A,
lower panel) and it may represent a cell-type-specific posttransla-
tional modification of Cdt1 in PHKs. Upregulation of Cdt1 pro-
tein also occurs inRPE1-E7 cells (Fig. 4A, lower panel). Also,while
bleomycin treatment led to a reduction of Cdt1 in the vector con-
trol cells, no significant change in the steady-state level of Cdt1was
seen in RPE1-E7 cells (Fig. 4B). Consistent with what was ob-
served previously (43), Cdt1 levels dropped after UV treatment in
RPE1-Babe cells (Fig. 4B). Interestingly, unlike what was observed
with bleomycin treatment, UV treatment reduced the steady-state
level of Cdt1 in E7-expressing RPE1 cells, although the reduction
is not as much as that in the vector control cells (Fig. 4B).
We also examined Cdt1 protein stability in E7-expressing
RPE1 cells. Consistent with the steady-state level of Cdt1, the half-
life of Cdt1 in E7-expressing cells is longer than that in the vector-
containing cells (3 h versus1 h) (Fig. 4C). The half-life of Cdt1
in the vector-containing RPE1 cells upon DNA damage was not
able to be measured, as the steady-state level of Cdt1 in these cells
was very low upon bleomycin treatment, even in the presence of
MG132, the proteasome inhibitor (Fig. 4C). In contrast, upon
bleomycin treatment, the half-life of Cdt1 in E7-expressing
cells did not change significantly (Fig. 4C). These results dem-
FIG 4 Upregulation of Cdt1 in E7-expressing cells. (A) Cdt1 levels in PHKs (upper panel) and RPE1 cells (lower panel) expressing E7 or vector were examined
byWestern blotting.-actinwas used as a loading control. CE-HPVcells (upper panel) were also examined forCdt1 expression. (B)Cdt1 levels inRPE1 cells after
bleomycin (5g/ml for 48 h) and UV (1min, followed by 48 h of UV-free incubation) treatment were examined byWestern blotting (upper panel). -actin was
used as a loading control. Steady-state levels of Cdt1 were quantified and normalized to -actin (lower panel). The ratio between Cdt1 and -actin in untreated
control RPE1-Babe cells was set as 1. Con, control; Bleo, bleomycin. (C) RPE1 E7-expressing cells were treated with bleomycin (5 g/ml) or PBS. Forty-eight
hours later, cells were incubated withMG132 for 4 h, treated with 25g/ml cycloheximide (CHX) in the absence ofMG132, and harvested at the indicated times.
The stability of Cdt1 wasmonitored by immunoblot analyses (upper panel). Relative quantification of Cdt1 protein levels was assessed by densitometric analysis
(lower panel). The average of 3 independent experiments is given.
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onstrate that Cdt1 expression in E7-expressing cells is regu-
lated at the posttranslational level. Since Cdt1 is an E2F-regu-
lated gene that is negatively regulated by pRb (44), it is
expected that Cdt1 transcription should also be upregulated in
E7-expressing cells.
Cdt1plays an important role inE7-induced rereplication.To
confirm the role of Cdt1 in E7-induced rereplication, we used
siRNAs targeting Cdt1. These siRNAs were previously demon-
strated to downregulate Cdt1 expression after transfection into
cultured cells (28, 29). Transfection of siRNAs targeting Cdt1 ef-
ficiently reduced the steady-state levels of Cdt1 in RPE1-E7 and
RPE1-Babe cells (Fig. 5A). For RPE1-E7 cells, the Cdt1 levels were
also reduced by siRNA after bleomycin treatment (Fig. 5A, lower
panel). In one case (Cdt1-siRNA001), the level of Cdt1 was still
higher than that in the vector control cells; in the other case (Cdt1-
siRNA002), the level of Cdt1 was reduced to that in the vector
control cells (Fig. 5A, upper panel). Therefore, knocking down of
Cdt1 by these siRNAs should not disrupt normal DNA replication
initiation. We then used these siRNAs to assess the role of Cdt1 in
E7-induced rereplication. Notably, the percentage of polyploidy
in siRNA-transfected RPE1 cells expressing E7 was lower than
those shown in Fig. 1A (13% versus 26%), probably due to the
toxicity of the transfection reagent. Nonetheless, knocking down
Cdt1 by Cdt1-siRNA001 led to a statistically significant reduction
in polyploidy formation in RPE1 cells expressing E7 after bleomy-
cin treatment (Fig. 5B). Similar results were obtained using Cdt1-
siRNA 002 (data not shown). Moreover, knocking down of Cdt1
by Cdt1-siRNA001 led to a significant reduction of BrdU incor-
poration for RPE1-E7 cells with 4C DNA content (Fig. 5C).
These results demonstrate that upregulation of Cdt1 is important
for E7 to induce rereplication and contributes to the polyploid
formation in E7-expressing cells.
FIG 5 Downregulation of Cdt1 impairs the ability of E7 to induce rereplication. (A) RPE1-E7 and RPE1-Babe cells were transfected with Cdt1-siRNAs. Some
dishes of RPE1-E7 cells were treated with bleomycin (4 g/ml) for the final 36 h. Seventy-two hours posttransfection, cells were harvested and lysed and Cdt1
protein levels were analyzed by immunoblot. -tubulin or -actin was used as a loading control. Bleo, bleomycin. (B) RPE1-E7 and RPE1-Babe cells were
transfected with Cdt1-siRNAs. The transfected cells were then treated with bleomycin (4 g/ml). Seventy-two hours posttransfection, cells were harvested,
stainedwith PI, and analyzed by flow cytometry. A representative experiment of 4 individual experiments is shown in the upper panel. Data of 4 experiments from
RPE1-E7 cells are summarized in the lower panel. Error bars reflect the standard deviations of themean. (C)RPE1-E7 cells were transfectedwithCdt1-siRNA001.
Thirty-six hours later, cells were treated with bleomycin (4 g/ml) for an additional 36 h. Cells were labeled with BrdU for 2 h before collection. Cells were then
stained with anti-BrdU antibody, counterstained with PI, and analyzed by flow cytometry. The percentages of BrdU-positive cells with DNA content4C are
indicated. Data from a representative of 3 experiments are shown. UTFC, untransfected control; NS-siRNA, nonsilencing siRNA.
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DISCUSSION
We have recently shown that in response to microtubule disrup-
tion, HPV E7 abrogates the postmitotic checkpoint to induce en-
doreduplication (25). In this study, we demonstrated that upon
DNA damage, cells expressing HPV oncogene E7 did not arrest at
the G1 checkpoint, likely due to G1 checkpoint abrogation as pre-
viously described (45–47). However, E7 does not alleviate the G2
checkpoint. While being arrested at G2, cells expressing E7 induce
rereplication. HPV E7 therefore induces polyploidy via different
mechanisms in response to different insults.We also show that the
DNA replication initiation factor Cdt1 is upregulated in E7-ex-
pressing cells and is important for E7-induced rereplication.
Compared with the G1 checkpoint, which is defective in HPV
E7-expressing cells (45–47), less attention has been paid to the
effect of HPV on the G2 checkpoint. While some studies suggest
that HPV E7 does not abrogate the G2 checkpoint in early-passage
cells, several groups of investigators had different opinions. Spe-
cifically,mouseNIH 3T3 cells expressingHPVE7were believed to
be defective for the G2 checkpoint in response to doxorubicin
treatment (22).However, the ability of E7-expressing cells to enter
into mitosis was not examined in this study. Notably, upon hy-
droxyurea treatment, more HPV-16 E7-expressing PHKs than
control cells were found in mitosis (24). It is likely that the G2
checkpoint in E7-expressing PHKsmay respond differently to dif-
ferent types of DNA-damaging agents. However, it is evident that
the percentage of E7-expressing cells entering mitosis in this case
is relatively small (0.9%) while the percentage of cells in G2 upon
hydroxyurea treatment is expected to increase significantly. Col-
lectively, these data suggest that although a small number of E7-
expressing cells can enter into mitosis in the presence of DNA
damage, the G2 checkpoint in these cells is largely intact. The con-
troversy between the previous studies and our current observation
regarding the function of the G2 checkpoint can therefore be ex-
plained by differences in data interpretation as well as experimen-
tal conditions.
During the HPV life cycle, several mechanisms that arrest cells
at the G2 checkpoint have been proposed. For example, the
HPV-16 E4 protein prevents the nuclear entry of the mitotic cy-
clin/Cdk (48). In suprabasal cells, E7 expression induced cytoplas-
mic accumulation of cyclin B1 and Cdk1 with inactivating phos-
phorylation and G2 arrest following S phase reentry (31).
Arresting cells at G2 may facilitate viral replication, as several vi-
ruses were found to replicate their genomes in the G2 phase (49).
Interestingly, it was suggested that Cdt1 contributes to HIV Vpr-
induced G2 arrest (50). On the other hand, activation of some of
the host DNA replication machinery might be needed for viral
DNA replication. In the case ofHPV,whose productive life cycle is
linked to epithelial differentiation, E7 establishes conditions per-
missive for viral DNA amplification (reference 31 and references
therein). Having an intact G2 checkpoint and activation of the
host DNA replication machinery, such as Cdt1, is therefore con-
sistent with what is expected for a role of E7 in the viral life cycle.
However, the E7 from the high-risk HPV types may also upregu-
late Cdt1 in the basal layer of stratified epithelia and induces the
host genome instability that contributes to carcinogenesis. Future
studies should examine the role of Cdt1 in HPV genome amplifi-
cation and the ability of E7 from the low-risk HPV types to up-
regulate Cdt1.
Since Cdt1 is the only known mammalian gene that efficiently
triggers rereplication when overexpressed (14, 41, 42), it is not
surprising that Cdt1 is upregulated in E7-expressing cells and
plays an important role in E7-induced rereplication. Notably,
Cdt1 overexpression-induced rereplication was observed only in
cancer cells previously; here, we show that E7 induces rereplica-
tion that is mediated by Cdt1 in primary and immortalized cells as
well. Unexpectedly, the Cdt1 protein remains relatively stable in
E7-expressing cells upon bleomycin treatment (Fig. 4C). Three E3
ubiquitin ligases, SCF-Skp2, APC/C, and DDB1-Cul4, have been
identified to target Cdt1 for proteolysis (43, 51–54). UV-depen-
dentCdt1 destruction ismediated byDDB1-Cul4 ubiquitin ligase,
which appears to be functioning in E7-expressing cells (Fig. 4B).
In PHKs expressing E6 and E7, the APC/C ubiquitin ligase com-
plex was shown to be active (55). It is possible that the SCF-Skp2
ligase is somehow compromised in cells expressing E7. Consistent
with this notion, in cervical cancers, the Skp2 ligase does not ap-
pear to be functioning (56). Interestingly, E7 was shown to bind
Skp2 and was ubiquitinated by the SCF-Skp2 ligase (57). It re-
mains to be determined whether the SCF-Skp2 ligase or some
other as-yet-unidentified E3 ubiquitin ligases are indeed altered in
E7-expressing cells. While we have demonstrated that Cdt1 ex-
pression in E7-expressing cells is regulated at posttranslational
levels, this does not rule out the possibility that E7 also regulates
Cdt1 expression at the transcriptional level. It is known that Cdt1
is an E2F-regulated gene that is negatively regulated by pRb (44).
pRb degradation may therefore contribute to E7-induced Cdt1
upregulation and rereplication.
Although our data demonstrate that Cdt1 plays an important
role in E7-induced rereplication, how DNA damage enhances re-
replication in E7-expressing cells is still not clear, since the level of
Cdt1 is not further increased in these cells upon DNA damage. A
straightforward explanation for DNA damage-enhanced rerepli-
cation in E7-expressing cells is that the G2 arrest allows extra time
for licensing of DNA replication to occur. However, merely extra
time may not be sufficient for the initiation of rereplication, as
DNA replication licensing factors are subjected to multiple regu-
lations in the G2 phase (58). DNA damage in E7-expressing cells
may inhibit cyclin A-Cdk1 activity and lead to an increased Cdt1
activity for licensing and therefore induces rereplication. It was
observed that Cdt1 phosphorylation by cyclin A-dependent ki-
nases reduces its affinity to DNA and that Cdk1 inactivation re-
sults in Cdt1 dephosphorylation and rebinding to chromatin/
nuclear matrix (59). Consistent with this observation, Cdk1 inac-
tivation in G2 phase promotes relicensing (60, 61). Alternatively,
the level of binding affinity to Cdt1 by its inhibitory protein gemi-
nin might be reduced upon DNA damage in E7-expressing cells.
Further studies are needed to test these possibilities.
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